Clinical trial · Interventional
Additional Effects of Perioperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy
Additional Effects of Perioperative Immunonutrition on Th1/Th2 Differentiation in Patients Undergoing Pancreaticoduodenectomy
NCT01969110CI-TRIAL-00012457unknownPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to investigate whether perioperative immunonutrition has additional effects on cell-mediated immunity in patients undergoing pancreaticoduodenectomy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bile Duct Tumor | Bile Duct Neoplasm | ALIAS | 0.90 |
| Pancreatic Tumor | Pancreatic Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Oral IMPACT | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Perioperative
- description
- Oral IMPACT (1 L/day) for 5 days before surgery and by enteral feeding after surgery
- interventionNames
- Dietary Supplement: Oral IMPACT
- type
- ACTIVE_COMPARATOR
- label
- Preoperative
- description
- Oral IMPACT 1000ml/day for 5 days (1 L/day) before surgery
- interventionNames
- Dietary Supplement: Oral IMPACT
Primary outcomes (1)
- measure
- plasma resolvin E1, cell-mediated immunity
- timeFrame
- 30 days
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * patients undergoing pancreaticoduodenectomy Exclusion Criteria: * age younger than 18 years old * ongoing infection * gastrointestinal obstruction * respiratory dysfunction * cardiac dysfunction * hepatic dysfunction * renal failure * history of recent immunosuppressive or immunological disease * preoperative evidence of widespread metastatic disease
References
Publications (0)
Data not yet available
No reference posted for this study.